Oxidative stress in patients with primary insomnia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 37, Issue 2, 2012, Pages 247-251

  Gulec, Mustafa ^a   Ozkol, Halil ^b   Selvi, Yavuz ^b   Tuluce, Yasin ^b   Aydin, Adem ^b   Besiroglu, Lutfullah ^b   Ozdemir, Pinar Guzel ^b  

^a ATATURK UNIVERSITY   (Turkey)

^b YUZUNCU YIL UNIVERSITY   (Turkey)

Author keywords

Antioxidant; Oxidative stress; Primary insomnia; Sleep

Indexed keywords

BIOLOGICAL MARKER; GLUTATHIONE; GLUTATHIONE PEROXIDASE; MALONALDEHYDE; MYELOPEROXIDASE; SUPEROXIDE DISMUTASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME BLOOD LEVEL; FEMALE; HUMAN; INSOMNIA; MALE; OXIDATIVE STRESS;

ADULT; BIOLOGICAL MARKERS; CATALASE; FEMALE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; HUMANS; LIPID PEROXIDATION; MALE; MALONDIALDEHYDE; MIDDLE AGED; OXIDATIVE STRESS; PEROXIDASE; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUPEROXIDE DISMUTASE;

EID: 84859591503     PISSN: 02785846     EISSN: 18784216     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2012.02.011     Document Type: Article

References (67)

1. Agargun M.Y., Kara H., Anlar O. The validity and reliability of the Pittsburgh Sleep Quality Index. Turk Psikiyatri Derg 1996, 7:107-115.
2. Akar F., Uydes-Dogan B.S., Buharalioglu C.K., Abban G., Heinemann A., Holzer P. Protective effect of cromakalim and diazoxide, and proulcerogenic effect of glibenclamide on indomethacin-induced gastric injury. Eur J Pharmacol 1999, 4:461-470.
3. APA (American Psychiatric Association) Diagnostic and statistical manual of mental disorders. Text revision (DSM-IV-TR) 2000, Washington, The American Psychiatric Association. 4th ed.
4. Aratani Y., Koyama H., Nyui S., Suzuki K., Kura F., Maeda N. Severe impairment in early host defense against Candida albicans in mice deficient in myeloperoxidase. Infect Immun 1999, 67:1828-1836.
5. Atmaca M., Kuloglu M., Tezcan E., Ustundag B. Antioxidant enzyme and malondialdehyde levels in patients with social phobia. Psychiatry Res 2008, 159:95-100.
6. Aytac B., Kayhan A., Devrim E., Durak I., Erguder I. The effects of sleep deprivation on oxidant/antioxidant status. Bull Clin Psychopharmacol 2007, 17:130-133.
7. Basta M., Chrousos G.P., Vela-Bueno A., Vgontzas A.N. Chronic insomnia and stress system. Sleep Med Clin 2007, 2:279-291.
8. Bixler E.O., Kales A., Soldatos C.R., Kales J.D., Healey S. Prevalence of sleep disorders in the Los Angeles metropolitan area. Am J Psychiatry 1979, 136:1257-1262.
9. Bonnet M.H., Berry R.B., Arand D.L. Metabolism during normal, fragmented, and recovery sleep. J Appl Physiol 1991, 71:1112-1118.
10. Bradley P.P., Priebat D.A., Christensen R.D., Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol 1982, 78:206-209.
11. Bridges A.B., Scott N.A., Parry G.J., Belch J.J. Age, sex, cigarette smoking and indices of free radical activity in healthy humans. Eur J Med 1993, 2:205-208.
12. Brown M.K., Naidoo N. The UPR and the anti-oxidant response: relevance to sleep and sleep loss. Mol Neurobiol 2010, 42:103-113.
13. Buysse D.J., Reynolds C.F., Monk T.H., Berman S.R., Kupfer D.J. The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research. Psychiatry Res 1989, 28:193-213.
14. Chesson A., Hartse K., Anderson W.M., Davila D., Johnson S., Littner M. Practice parameters for the evaluation of chronic insomnia. An American Academy of Sleep Medicine report. Standards of Practice Committee of the American Academy of Sleep Medicine. Sleep 2010, 23:237-241.
15. Cirelli C. Sleep disruption, oxidative stress, and aging: new insights from fruit flies. Proc Natl Acad Sci U S A 2006, 103:13,901-13,902.
16. D'Almeida V., Lobo L.L., Hipólide D.C., deOliveira A.C., Nobrega J.N., Tufik S. Sleep deprivation induces brain region-specific decreases in glutathione levels. Neuroreport 1989, 9:2853-2856.
17. D'Almeida V., Hipólide D.C., Azzalis L.A., Lobo L.L., Junqueira V.B., Tufik S. Absence of oxidative stress following paradoxical sleep deprivation in rats. Neurosci Lett 1997, 235:25-28.
18. Deby-Dupont G., Deby C., Lamy M. Neutrophil myeloperoxidase revisited: it's role in health and disease. Intensivmed Notfallmed 1999, 36:500-513.
19. Everson C.A., Laatsch C.D., Hogg N. Antioxidant defense responses to sleep loss and sleep recovery. Am J Physiol Regul Integr Comp Physiol 2005, 288:374-383.
20. Gopalakrishnan A., Ji L.L., Cirelli C. Sleep deprivation and cellular responses to oxidative stress. Sleep 2004, 27:27-35.
21. Gulec M., Selvi Y., Boysan M., Aydin A., Besiroglu L., Agargun M.Y. Ongoing or re-emerging subjective insomnia symptoms after full/partial remission or recovery of major depressive disorder mainly with the selective serotonin reuptake inhibitors and risk of relapse or recurrence: a 52-week follow-up study. J Affect Disord 2011, 134:257-265.
22. Halliwell B. Oxidative stress and neurodegeneration: where are we now?. J Neurochem 2006, 7:1634-1658.
23. Halliwell B., Gutteridge J.M.C. Free radicals in biology and medicine 2000, 617-624. London, Oxford University Press, Oxford Science Publications. 3rd ed.
24. Herken H., Uz E., Ozyurt H., Sogut S., Virit O., Akyol O. Evidence that the activities of erythrocyte free radical scavenging enzymes and the products of lipid peroxidation are increased in different forms of schizophrenia. Mol Psychiatry 2001, 6:66-73.
25. Herken H., Akyol O., Yilmaz H.R., Tutkun H., Savas H.A., Ozen M.E. Nitric oxide, adenosine deaminase, xanthine oxidase and superoxide dismutase in patients with panic disorder: alterations by antidepressant treatment. Hum Psychopharmacol 2006, 21:53-59.
26. Katsoulis K., Kontakiotis T., Spanogiannis D., Vlachogiannis E., Kougioulis M., Gerou S. Total antioxidant status in patients with obstructive sleep apnea without comorbidities: the role of the severity of the disease. Sleep Breath 2011, 10.1007/s11325-010-0456-y.
27. Klink M., Quan S.F. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest 1987, 91:540-546.
28. Klink M.E., Quan S.F., Kaltenborn W.T., Lebowitz M.D. Risk factors associated with complaints of insomnia in a general adult population. Influence of previous complaints of insomnia. Arch Intern Med 1992, 152:1634-1637.
29. Lavie L. Obstructive sleep apnoea syndrome-an oxidative stress disorder. Sleep Med Rev 2003, 7:35-51.
30. Lawrence R.A., Burk R.F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun 1976, 71:952-958.
31. LeBlanc M., Mérette C., Savard J., Ivers H., Baillargeon L., Morin C.M. Incidence and risk factors of insomnia in a population-based sample. Sleep 2009, 32:1027-1037.
32. Lee H.J., Kim S.H., Kim K.W., Um J.H., Lee H.W., Chung B.S. Antiapoptotic role of NF-kappa B in the auto-oxidized dopamine-induced apoptosis of PC12 cells. J Neurochem 2001, 76:602-609.
33. Leff J.A. Autoimmune and inflammatory diseases. Free radicals in diagnostic medicine 1994, 199-213. Plenum Press, New York. D. Armstrong (Ed.).
34. Leonard C.S., Michaelis E.K., Mitchell K.M. Activity-dependent nitric oxide concentration dynamics in the laterodorsal tegmental nucleus in vitro. J Neurophysiol 2001, 86:2159-2172.
35. Liu P.K., Arora T. Transcripts of damaged genes in the brain during cerebral oxidative stress. J Neurosci Res 2002, 70:713-720.
36. Mallon L., Broman J.E., Hetta J. Relationship between insomnia, depression, and mortality: a 12-year follow-up of older adults in the community. Int Psychogeriatr 2000, 12:295-306.
37. Matkovics B., Szabo L., Varga I.S. Determination of enzyme activities in lipid peroxidation and glutathione pathways (in Hungarian). Lab Diagn 1988, 15:248-249.
38. Metodiewa D., Koska C. Reactive oxygen species and reactive nitrogen species: relevance to cyto(neuro)toxic events and neurologic disorders. An overview. Neurotox Res 2000, 1:197-233.
39. Morin C.M., LeBlanc M., Daley M., Gregoire J.P., Mérette C. Epidemiology of insomnia: prevalence, self-help treatments, consultations, and determinant of help-seeking behaviors. Sleep Med 2006, 7:123-130.
40. Ohayon M.M. Prevalence of DSM-IV diagnostic criteria of insomnia: distinguishing insomnia related to mental disorders from sleep disorders. J Psychiatr Res 1997, 31:333-346.
41. Ohayon M.M. Prevalence, diagnosis and treatment of chronic insomnia in the general population. Proceedings of the satellite symposium new developments in the treatment of insomnia-do they really have impact on the primary care settings? 2001, Medical Forum International, Zeist.
42. Ohayon M.M., Sagales T. Prevalence of insomnia and sleep characteristics in the general population of Spain. Sleep Med 2010, 11:1010-1018.
43. Ohayon M.M., Smirne S. Prevalence and consequences of insomnia disorders in the general population of Italy. Sleep Med 2002, 3:115-120.
44. Ohayon M.M., Caulet M., Guilleminault C. How a general population perceives its sleep and how this relates to the complaint of insomnia. Sleep 1997, 20:715-723.
45. Ozkol H., Koyuncu I., Tuluce Y. Some medicinal plants counteract alterations of neuroendocrine stress response system, oxidative and nitrosative stress caused by repeated restraint in rats. J Med Plants Res 2011, 5:4360-4368.
46. Ozkol H., Tuluce Y., Koyuncu I. Subacute effect of cigarette smoke exposure in rats: protection by pot marigold (Calendula officinalis L.) extract. Toxicol Ind Health 2011, 10.1177/0748233711401263.
47. Ozturk L., Mansour B., Yuksel M., Yalcin A.S., Celikoglu F., Gokhan N. Lipid peroxidation and osmotic fragility of red blood cells in sleep-apnea patients. Clin Chim Acta 2003, 332:83-88.
48. Pal Y.B. Cellular defenses against damage from reactive species. Physiol Rev 1994, 74:139-162.
49. Placer Z.A., Cushman L.L., Johnson B.C. Estimation of products of lipid peroxidation (as malonyldialdhyde) in biochemical systems. Anal Biochem 1966, 16:359-364.
50. Quera-Salva M.A., Orluc A., Goldenberg F., Guilleminault C. Insomnia and use of hypnotics: study of a French population. Sleep 1991, 14:386-391.
51. Raichle M.E., Gusnard D.A. Appraising the brain's energy budget. Proc Natl Acad Sci U S A 2002, 99:10,237-10,239.
52. Ramanathan L., Gulyani S., Nienhuis R., Siegel J.M. Sleep deprivation decreases superoxide dismutase activity in rat hippocampus and brainstem. Neuroreport 2002, 13:1387-1390.
53. Regoli F., Principato G. Glutathione, glutathione dependent and antioxidant enzymes in mussel, Mytilus galloprovincialis, exposed to metals under field and laboratory conditions: implications for the use of biochemical biomarkers. Aquat Toxicol 1995, 31:143-164.
54. Reimund E. The free radical flux theory of sleep. Med Hypotheses 1994, 43:231-233.
55. Reite M., Buysse D., Reynolds C., Mendelson W. The use of polysomnography in the evaluation of insomnia. Sleep 1995, 18:58-70.
56. Savas H.A., Herken H., Yurekli M., Uz E., Tutkun H., Zoroglu S.S., et al. Possible pathopsychological role of nitric oxide and adrenomedullin in bipolar affective disorder. Neuropsychobiology 2002, 45:57-61.
57. Schulz R., Mahmoudi S., Hattar K., Sibelius U., Olschewski H., Mayer K. Enhanced release of superoxide from polymorphonuclear neutrophils in obstructive sleep apnea: impact of continuous positive airway pressure therapy. Am J Respir Crit Care Med 2000, 162:566-570.
58. Sedlak J., Lindsay R.H.C. Estimation of total, protein bound and nonprotein sulfhydryl groups in tissue with Elmann's reagent. Anal Biochem 1968, 25:192-205.
59. Selvi Y., Ozkol H., Tuluce Y., Besiroglu L., Ozdemir P.G. Chronotypes and oxidative stress: is there an association?. Biol. Rhythm Res. 2011, 10.1080/09291016.2010.548927.
60. Smith A.J., Blumenfeld H., Behar K.L., Rothman D.L., Shulman R.G., Hyder F. Cerebral energetics and spiking frequency: the neurophysiological basis of fMRI. Proc Natl Acad Sci U S A 2002, 99:10,765-10,770.
61. Suer C., Dolu N., Artis A.S., Sahin L., Yilmaz A., Cetin A. The effects of long-term sleep deprivation on the long-term potentiation in the dentate gyrus and brain oxidation status in rats. Neurosci Res 2011, 70:71-77.
62. Tsaluchidu S., Cocchi M., Tonello L., Puri B.K. Fatty acids and oxidative stress in psychiatric disorders. BMC Psychiatry 2008, 17:1-5.
63. Van Cauter E., Spiegel K., Tasali E., Leproult R. Metabolic consequences of sleep and sleep loss. Sleep Med 2008, 9:23-28.
64. Virit O., Altindag A., Yumru M., Dalkilic A., Savas H.A., Selek S. Defect in the antioxidant defense system in schizophrenia. Neuropsychobiology 2009, 60:87-93.
65. Welstein L., Dement W.C., Redington D., Guilleminault C. Insomnia in the San Francisco Bay area: a telephone survey. Sleep/wake disorders: natural history, epidemiology, and long-term evolution 1983, 29-35. Raven Press, New York. C. Guilleminault, E. Lugaresi (Eds.).
66. Whanger P.D. Selenium and the brain: a review. Nutr Neurosci 2001, 4:81-97.
67. Yilmaz Z., Celik I. Neurotoxic and immunotoxic effects of Indole-3-butyric acid on rats at subacute and subchronic exposure. Neurotoxicology 2009, 30:382-385.